Hema To Team

About hema.to

hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as well as patients. hema.to is a CE-IVD, FDA registered and already in routine use by leading hematology laboratories. Founded in 2021, hema.to’s mission is to make clinical analysis of cytometry data completely objective, to enable doctors to personalize treatment to their patient’s unique immune system.

Press releases

Hema To Team
Press
26. June 2023

hema.to raises €3.6M to bring precision diagnostics to immune medicine using AI-assisted analysis of single-cell blood data

Making clinical analysis of blood data automated & personalized hema.to’s mission is to make the clinical analysis of blood data — called cytometry — automated and fully objective to enable personalization of treatment to every person’s unique immune system. Currently, even for skilled laboratory personnel, cytometry analysis is a laborious process that has a large degree of subjectivity. hema.to’s mission is now backed by Elaia Partners, Heal Capital and High-Tech Gründerf
 

Info & Contact

Web:
hema.to

Address

hema.to GmbH
Ainmillerstr. 22
80801 Munich

Sector

Dr. Nikolaus Raupp

Senior Investment Manager